Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-08
Michael Scott Robeson
High Impact
Associate Professor
Faculty Researcher
Biomedical Informatics, College of Medicine
1 h-index
7 pubs
4 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Michael Scott Robeson's research focuses on the intersection of microbial communities and host physiology, with a particular emphasis on the gut microbiome. His work investigates how dietary factors and disease states influence the composition and function of these microbial ecosystems. Robeson has published studies on the gut microbiota's association with vascular inflammation in metabolic syndrome, the impact of iron-deficient diets on enteric infections in mouse models, and the relationship between gut microbes and depressive-like behaviors following chemotherapy. He also explores the transcriptomic and morphological changes associated with diabetes progression in rat models. His research utilizes bioinformatics and molecular techniques to analyze complex biological data, including genomic and proteomic datasets. Robeson's collaborators include researchers from the University of Arkansas for Medical Sciences, indicating a network focused on biomedical informatics and related fields.
Metrics
- h-index: 1
- Publications: 7
- Citations: 4
Selected Publications
-
Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs (2026)
-
Late-in-life treadmill training mitigates gut microbiome imbalances and cardiovascular disease risk in mice (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
Changes in gut, microbiome, and cognition after doxorubicin, cyclophosphamide, and paclitaxel chemotherapy treatment (2026)
-
Implications of cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy on hippocampal-dependent cognition and gut microbiome (2025)
-
The effect of obesity and dietary soy protein with different isoflavone levels on fecal microbial composition in lean and obese Zucker rats over 9- and 18-week periods (2025)
-
Oat bran fiber protects against radiation-induced disruption of gut barrier dynamics and mucosal damage (2025)
-
Obesity and Dietary Soy Protein With Different Isoflavone Levels Alter Fecal Microbial Composition in Zucker Rats Over 9- and 18-Week Periods (2025)
-
Fueling the fire: colonocyte metabolism and its effect on the colonic epithelia (2025)
-
MOSHPIT: accessible, reproducible metagenome data science on the QIIME 2 framework (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Gut Microbiome Diversity and Composition Changes Post Allogeneic Hematopoietic Stem Cell Transplant (AlloSCT): A Single-Center Prospective Analysis (2024)
-
Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level (2024)
-
Bioinformatics challenges for profiling the microbiome in cancer: pitfalls and opportunities (2024)
-
Soy Protein Concentrate With Low and High Isoflavones Can Reverse Non-alcoholic Fatty Liver Disease Caused by Obesity and Alter Gut Microbial Composition (2024)
Research Interests
Dr. Robeson currently focuses on the human microbiome and its relationship to nutrition and cancer therapeutics, while also contributing to the development of bioinformatics tools to aid in these studies. Dr. Robeson’s research interests center on the human cancer microbiome, which is an important and booming area of research and is in line with the current UAMS plan for NCI designation, as it has become increasingly clear that the efficacy of anticancer treatments is not only affected by host genetic and immunological factors but are also substantially mediated by the host microbiome. Microbial community dynamics, disease resistance, human health, and agricultural productivity are all highly affected, or dependent upon, microbes. Dr. Robeson’s research integrates bioinformatics, microbial ecology, and integrative multi-omics technologies, to study host-microbe interactions. Particularly those that affect human health and agricultural productivity.; Microbiome; Microbiome Data Science; Microbial Ecology; Human Microbiome; Bioinformatics; eDNA; Phylogenetics; Cancer Microbiome; Microbiome Science; Metagenomics; Host-microbe Interactions
Grants & Funding
As listed on this researcher's institutional profile.
- Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi NCI Co-Investigator
- Improvement of cellular immunotherapy during dysbiosis- Resubmission NIH Co-Investigator
- Improvement of cellular immunotherapy during dysbiosis NIH/Nat. Cancer Institute Principal Investigator
- Regulation of macrophage function during acute infection with Plasmodium NIH Co-Investigator
- Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH Co-Investigator
- Center for Translational Pediatric Research (CTPR) NIH/NIGMS Other Key Personnel
- Obstructive Sleep Apnea Arkansas Research Alliance Co-Investigator
Collaboration Network
Top Collaborators
Christopher E. Randolph
Arkansas Children's Hospital
6 shared publications
In database
- Progression of diabetes is associated with changes in the ileal transcriptome and ileal‐colon morphology in the UC Davis Type 2 Diabetes Mellitus rat
- Bacterial and Fungal Adaptations in Cecum and Distal Colon of Piglets Fed With Dairy-Based Milk Formula in Comparison With Human Milk
- Colonic epithelial hypoxia remains constant during the progression of diabetes in male UC Davis type 2 diabetes mellitus rats
- Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level
- The effect of obesity and dietary soy protein with different isoflavone levels on fecal microbial composition in lean and obese Zucker rats over 9- and 18-week periods
Showing 5 of 6 shared publications
Kanishka Manna
Winthrop Rockefeller Foundation
6 shared publications
In database
- Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Showing 5 of 6 shared publications
Stephanie D. Byrum
St. Jude Children's Research Hospital
6 shared publications
In database
- Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Showing 5 of 6 shared publications
Intawat Nookaew
University of Arkansas for Medical Sciences
6 shared publications
In database
- Short‐Term Ingestion of Essential Amino Acid Based Nutritional Supplements or Whey Protein Improves the Physical Function of Older Adults Independently of Gut Microbiome
- Oat bran fiber protects against radiation-induced disruption of gut barrier dynamics and mucosal damage
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Showing 5 of 6 shared publications
David W. Ussery
University of Arkansas for Medical Sciences
5 shared publications
In database
- Mash-based analyses of Escherichia coli genomes reveal 14 distinct phylogroups
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Prashanthi Dharanipragada
APLA Health (US)
5 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Duah Alkam
Winthrop Rockefeller Foundation
5 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Nathan L. Avaritt
University of Arkansas for Medical Sciences
5 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Charity L. Washam
University of Arkansas for Medical Sciences
5 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Samuel G. Mackintosh
University of Arkansas for Medical Sciences
5 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Shirley H. Lomeli
APLA Health (US)
5 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Gatien Moriceau
APLA Health (US)
5 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Alan J. Tackett
University of Arkansas for Medical Sciences
5 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs
Reza Hakkak
Arkansas Children's Hospital
5 shared publications
In database
- Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model
- Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level
- The effect of obesity and dietary soy protein with different isoflavone levels on fecal microbial composition in lean and obese Zucker rats over 9- and 18-week periods
- Soy Protein Concentrate With Low and High Isoflavones Can Reverse Non-alcoholic Fatty Liver Disease Caused by Obesity and Alter Gut Microbial Composition
- Obesity and Dietary Soy Protein With Different Isoflavone Levels Alter Fecal Microbial Composition in Zucker Rats Over 9- and 18-Week Periods
Takeo Shibata
Kanazawa Medical University
4 shared publications
In database
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Similar Researchers
Based on overlapping research topics
Clayton Henrichson
Harding University Main Campus
Gut microbiota and health
Metabolism and Genetic Disorders
Microbial infections and disease research
Stewart A. Tackett
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Microbial infections and disease research
Genomics and Phylogenetic Studies
Ying Zhong
University of Arkansas for Medical Sciences
Gut microbiota and health
Metabolism and Genetic Disorders
Microbial infections and disease research
Jilliyn Jeu
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Microbial infections and disease research
Diet and metabolism studies
Heather Prowse
Hendrix College
Microbial infections and disease research
Genomics and Phylogenetic Studies
Bioinformatics and Genomic Networks
Mary Kathryn E Cheek
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Microbial infections and disease research
Genomics and Phylogenetic Studies